Description: Alfuzosin, which is available as UroXatral, is a prescription medicine that is called an “alpha blocker.” It is used in adult men to treat the symptoms of benign prostatic hyperplasia (BPH). Alfuzosin is thought to work by helping to relax the muscles in the prostate and the bladder, which may lessen the symptoms of BPH and improve urine flow.
Serious Side Effects
A serious adverse reaction from UroXatral is drop in blood pressure, especially when you start taking this medicine. This may lead to fainting or lightheadedness. UroXatral also carries the potential of causing cardiac arrhythmia in susceptible patients. Additionally, UroXatral/alfuzosin can impair the functioning of the liver and kidneys, according to the UroXatral drug label as reported by the FDA.
Common Side Effects
The most common side effects with UroXatral according to the UroXatral drug label are:
Less Common Side Effects
According to the UroXatral drug label, the following less common side effects may occur:
Understand Your Risks with the Rxight® Genetic Test
MD Labs’ Rxight® pharmacogenetic testing program is grounded in a process called “SNP genotyping” to ascertain a patient’s unique genetically modulated reaction to over 150 common prescription and OTC medications. Knowing your DNA blueprint enables you and your provider to decide the dosing that is safest, or to discontinue therapy and find an alternative medication. All that is required is a simple cheek swab of your DNA, which is sent to our lab for processing, after which your results will be reviewed with a pharmacist with expertise in pharmacogenetic testing.
How Does Pharmacogenetic Testing Work?
UroXatral is predominantly metabolized in the body by an enzyme in the liver to inactive chemicals. If you are a “slow metabolizer” of this enzyme according to your genes, you will be at greater risk for side effects or toxicity. Additionally, alfuzosin is not recommended if you are already taking any medicine which can block the action of that enzyme – as the risk for potentially fatal irregular heartbeat induced by this drug is increased at higher concentrations.
Contributors to this Article:
Michael Sapko, MD, PhD; Deborah Kallick, PhD, Medicinal Chemistry
Read more about Rxight® pharmacogenetic testing